National Surveillance for Severe Adverse Events Associated with Treatment of Latent Tuberculosis Infection

Severe adverse events (SAEs) to Tuberculosis (TB) treatment are rare but continue to be a public health problem. In order to continue to determine risk factors and to monitor trends of SAEs related to the treatment of Latent TB Infection (LTBI), CDC requests approval to continue collecting SAE reports through NSSAE. These reports are from healthcare providers and health departments (local/state/territorial) from any of the 60 reporting areas for the National TB Surveillance System (NTSS)OMB No.0920-0026, Exp. Date 12/31/2019. Data will be collected on each occurrence of SAEs reported by healthcare providers through the local and state health departments. Data collection is initiated when a health department is notified of a person hospitalized with severe adverse reactions to the medications prescribed to treat LTBI. Since OMB approval of the NSSAE collection form 3 years ago, the project officers have received 66 reports of SAEs.

The latest form for National Surveillance for Severe Adverse Events Associated with Treatment of Latent Tuberculosis Infection expires 2021-03-31 and is listed under ICR 201802-0920-002.

Reporting Severe Adverse Events (Hospitalization or Death) Associated with Treatment of Latent Tuberculosis Infection (LTBI) - Med Clerk

Federal Enterprise Architecture: Health - Health Care Services

Review document collections for all forms, instructions, and supporting documents - including paper/printable forms.